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Background: The purpose of this study is to evaluate the microbiological profile and treatment outcomes of
vancomycin-resistant Gram-positive bacterial endophthalmitis. Medical records of all patients with Gram-positive
bacterial endophthalmitis resistant to vancomycin presenting between 1 January 2005 and 31 December 2010
were reviewed in this noncomparative, consecutive, retrospective case series. Favorable outcome was defined as a
best-corrected visual acuity of ≥20/200.
Results: Out of 682 culture-positive endophthalmitis isolates, 448/682 (65.6%) were associated with Gram-positive
bacteria. In vitro resistance to vancomycin was noted in 7/448 (1.56%). Three cases were posttraumatic, three were
postoperative, and one was endogenous in origin. Four Bacillus isolates, two Staphylococcus isolates, and an
Enterococcus isolate were resistant. Isolates resistant to vancomycin were sensitive in vitro to ciprofloxacin in 6/7
(86%) patients. Presenting visual acuity was light perception in all seven cases. Favorable outcome was achieved in
only 1/7 (14.3%) cases.
Conclusions: Vancomycin-resistant endophthalmitis is uncommon and usually associated with poor visual
outcome. Bacillus sp. is the most frequent Gram-positive bacteria resistant to vancomycin. Fluoroquinolones like
ciprofloxacin may be considered as a useful alternative in vancomycin-resistant endophthalmitis.
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Management of endophthalmitis includes performing ei-
ther vitreous tap/biopsy or vitrectomy and institution of
appropriate intravitreal antibiotic therapy. Gram-positive
bacteria are the most common cause of both exogenous
and endogenous endophthalmitis. Vancomycin is consi-
dered to be the drug of choice for empiric coverage of
Gram-positive organisms in endophthalmitis. However,
there are few reports of vancomycin resistance in
Gram-positive bacterial isolates (Enterococcus sp. and
Staphylococcus sp.) associated with endophthalmitis [1,2].
The current study evaluates microbiological characteristics
and visual outcome of vancomycin-resistant Gram-positive
bacterial endophthalmitis in a large clinical series.* Correspondence: avinash@lvpei.org
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In this noncomparative, consecutive case series, the
medical records of all patients with culture-proven, cli-
nically diagnosed, infective bacterial endophthalmitis be-
tween January 2005 and December 2010 were reviewed
after obtaining institutional review board approval. The
study followed the Declaration of Helsinki guidelines.
Data collected included demographic details, etiology,
complications of surgery, duration of symptoms, interval
between the event and presentation to the institute, use
of medication (topical or systemic), examination findings
(presenting visual acuity, presence of hypopyon, pre-
sence of vitreous cells, and optic disk visibility), ultra-
sonography (with attention to the presence of vitreous
membranes), and microbiology (including culture and
sensitivity). The Endophthalmitis Vitrectomy Study re-
commendations [3] (vitrectomy reserved for eyes withOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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for eyes with presenting vision of hand motions at 1 m
or more) were followed in postoperative endophthalmitis
eyes only. Vitrectomy was performed in all eyes with
traumatic and endogenous endophthalmitis. All eyes re-
ceived intravitreal vancomycin (1.0 mg in 0.1 ml) and
amikacin (0.4 mg in 0.1 ml) or ceftazidime (2.25 mg in
0.1 ml). Treatment and management decisions were
made by the individual treating physicians without a pre-
defined study protocol. The undiluted vitreous biopsy
samples were stained with Gram stain for microscopy
and also inoculated directly onto 5% sheep blood agar,
chocolate agar, Sabouraud dextrose agar, thioglycollate,
and brain-heart infusion broth. A culture was considered
positive when there was growth of the same organism
on two or more media, confluent growth at the site of
inoculation on one solid medium, or growth in one
medium with consistent microscopy findings. Antibiotic
sensitivity was tested by disk diffusion technique. A
best-corrected visual acuity of 20/200 or more at final
follow-up was defined as a favorable outcome.
Results
Of 682 culture-positive endophthalmitis, 448 (65.6%)
were associated with Gram-positive bacteria. Resistance
to vancomycin was noted in 7 (1.56%) cases. Mean age
of the patients was 35 years (range 4 to 70 years). Three
cases were posttraumatic, three were postoperative, and
one was endogenous in origin. All cases, except the one
with endogenous endophthalmitis, presented within 1
week of symptoms. Presenting visual acuity was only
light perception in all seven cases. The details of the pri-
mary and secondary interventions are summarized in
Table 1. Vancomycin resistance was commonly noted in
Bacillus sp. (4 of 96, 4.17%), followed by StaphylococcusTable 1 Demographic characteristics, etiology, management,













1 20 M Trauma 1 LP CTR + PPV
+ IOAB
PPV + M
+ C + T
2 70 F Postcataract
surgery
5 LP PPV + IOAB +
IOL explant
Nil
3 70 M Postcataract
surgery
1 LP PPV + IOAB C + T
4 5 M Trauma 1 LP CTR + PPL +
PPV + IOAB
Nil
5 4 F Trauma 3 HM CTR + PPL +
PPV + IOAB
Nil
6 60 M Postcataract
surgery
6 LP PPV + IOAB Nil
7 16 F Endogenous 20 LP PPV + IOAB Enucleation
C, ceftazidime; T, triamcinolone; D, dexamethasone; V, vancomycin; A, amikacin; M,
corneal tear repair; PPV, pars plana vitrectomy; IOAB, intraocular antibiotic; PPL, par
perception; NLP, no light perception; V/A, visual acuity.sp. (2 of 80, 2.5%) and Enterococcus sp. (1 of 5, 20%). Six
of the seven isolates also had multidrug resistance. Six
(86%) isolates were sensitive to ciprofloxacin followed by
4 (57%) each to gentamicin, gatifloxacin, and ceftazidime
(Table 2). Favorable outcome was achieved in 1/7
(14.3%) patients. Five eyes went into phthisis, while one
patient achieved counting fingers at 1 m.
Discussion
Vancomycin is a widely used glycopeptide antibiotic that is
effective against most Gram-positive bacteria including
Streptococcus, Staphylococcus, and Bacillus species. It is
commonly used for the treatment of methicillin-resistant
coagulase-negative Staphylococcus and methicillin-resistant
Staphylococcus aureus (MRSA) infections. Vancomycin
kills bacteria by binding irreversibly to D-alanyl-D-alanine
moieties of the N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) peptides. This inhibits the syn-
thesis and cross-linking of the NAM/NAG polymers that
form the backbone of the cell wall. Resistant mutants are
very rare, except for vancomycin-resistant Enterococcus.
The mechanism of acquiring vancomycin resistance includes
conversion of D-Ala-D-Ala to the depsipeptide D-Ala-D-Lac
or to D-Ala-D-Ser, leading to altered cross-linkages in the
peptidoglycans of the cell wall [4].
In the Endophthalmitis Vitrectomy Study, 100% of the
Gram-positive bacteria were susceptible to vancomycin
[5]. However, in the current series, three acute-onset
postoperative endophthalmitis patients with Gram-
positive organisms (Staphylococcus epidermidis, Bacillus
sp., and Enterococcus faecalis) were resistant to vanco-
mycin. There have been reports of using vancomycin as
a prophylaxis either intracamerally or in the irrigating
solution during cataract surgery [6,7] which may pos-














GPB Ciprofloxacin V + C T CF - 1 m 3 Unfavorable
GPC Gatifloxacin V + A D LP 3 Unfavorable
GPB Ciprofloxacin V + A T 20/20p 4 Favorable
GPB Cephalexin V + C
+ Am
- LP 6 Unfavorable
GPB Ciprofloxacin V + C - LP 3 Unfavorable
GPC Ciprofloxacin V + C - LP 6 Unfavorable
GPC Ciprofloxacin V + A - NLP 6 Unfavorable
membranectomy; GPC, Gram-positive cocci; GPB, Gram-positive bacilli; CTR,
s plana lensectomy; Am, amphotericin B; CF, counting fingers; LP, light
Table 2 Antimicrobial susceptibility of vancomycin-resistant Gram-positive organisms
Number Bacteria Cefa Cefta Ch Gen Cipro Gati Oflox Vanco Amika
1 Bacillus macerans R S R S S R R R S
2 Staphylococcus epidermidis R R R R S S S R S
3 Bacillus species R S R S S S S R S
4 Bacillus cereus R R R S S R R I R
5 Bacillus species S S S S S S S R S
6 Enterococcus faecalis R R R R R R R I R
7 Staphylococcus aureus S S R R S S R I R
Amika, amikacin; Cefa, cefazolin; Cefta, ceftazidime; Ch, chloramphenicol; Gen, gentamicin; Cipro, ciprofloxacin; Gati, gatifloxacin; Oflox, ofloxacin; Vanco,
vancomycin; S, sensitive; R, resistant; I, intermediate.
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was the most common Gram-positive bacteria resistant
to vancomycin. In a previous report, resistance among
Bacillus sp. to vancomycin was noted in 10 of 31
(32.3%) organisms isolated between 1991 and 1998 [8].
In another large case series reported by Miller and asso-
ciates, all of the Bacillus sp. isolates were sensitive to
vancomycin [9].
In the current study, most of the patients had poor
visual outcomes. This can be attributed to multiple fac-
tors including initial delay in presentation, microbial re-
sistance, and virulence of the organism, as well as
concurrent trauma in some patients. It was interesting
to note that these vancomycin-resistant Gram-positive
organisms were most likely to be sensitive to the
second-generation fluoroquinolone ciprofloxacin.
Quinupristin-dalfopristin, linezolid, daptomycin, and
tigecycline have been used to treat systemic infections
caused by vancomycin-resistant bacteria, though there
are no formal recommendations for treatment of such
endophthalmitis cases, given the paucity of these infec-
tions. Quinupristin/dalfopristin is a synthetic, parenteral,
streptogramin antibiotic that acts by sequential ribosomal
binding to inhibit protein synthesis and is effective in
vitro against Enterococcus faecium, MRSA, Streptococcus
pneumoniae, and other Gram-positive cocci. Hernandez-
Da Mota reported successful treatment of endophthalmitis
due to vancomycin-resistant S. aureus by administration
of intravitreal 0.4 mg/0.1 ml quinupristin/dalfopristin in-
jection [10]. Linezolid is an oxazolidinone antibiotic that
inhibits protein synthesis by binding to domain V of the
235 ribosomal RNA of the 50S subunit of bacterial ribo-
somes and is active in vitro against vancomycin-resistant
Enterococcus, MRSA, vancomycin-resistant S. aureus, and
penicillin-resistant S. pneumoniae. Systemic linezolid has
been reported in the successful treatment of vancomycin-
resistant E. faecium endophthalmitis following penetrating
keratoplasty [11]. Daptomycin is a lipopeptide that binds
to the bacterial cytoplasmic membrane to effect release of
intracellular ions and cell death. It demonstrates good
in vitro bactericidal activity for vancomycin-resistantstrains of bacteria accounting for endophthalmitis, includ-
ing S. epidermidis, S. aureus, S. pneumoniae, E. faecalis,
and E. faecium [12]. Comer and colleagues demonstrated
that administration of 200 μg of intravitreal daptomycin
was safe and efficacious in a rabbit model of bacterial
endophthalmitis [13]. Tigecycline is a glycylcycline anti-
biotic that binds to the 30S ribosomal subunit to inhibit
protein synthesis. It is active in vitro against MRSA, other
multidrug-resistant Gram-positive cocci, and many Gram-
negative bacilli [14].
Limitations of this report include the fact that the iso-
lates were vancomycin-resistant by disk diffusion method
which was not confirmed by MIC and the small number
of cases in this retrospective series. However, it should be
noted that these vancomycin-resistant organisms have
been reported to be resistant to multiple other antibiotics
[15]. In the current series, six of the seven isolates showed
multidrug resistance.Conclusions
In conclusion, vancomycin resistance among Gram-positive
isolates is an uncommon but an emerging problem. The
magnitude of antibiotic resistance requires ongoing surveil-
lance and periodic reporting from individual laboratories.Competing interests
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